<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736121</url>
  </required_header>
  <id_info>
    <org_study_id>STX2001</org_study_id>
    <nct_id>NCT04736121</nct_id>
  </id_info>
  <brief_title>Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR &amp; ORR in Unresectable Hepatocellular Carcinoma Patients</brief_title>
  <acronym>DOORwaY90</acronym>
  <official_title>A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety &amp; Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR &amp; ORR in Unresectable Hepatocellular Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirtex Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bright Research Partners</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sirtex Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using&#xD;
      SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in&#xD;
      patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C.&#xD;
&#xD;
      SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90 (Y-90), with a&#xD;
      size between 20 and 60 microns in diameter. Y-90 is a high-energy pure beta-emitting isotope&#xD;
      with no primary gamma emission.&#xD;
&#xD;
      SIR-Spheres are indicated for the local tumor control of unresectable hepatocellular&#xD;
      carcinoma (HCC) in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1 and B2,&#xD;
      maximal single lesion size of 8 cm, no macrovascular invasion, well-compensated liver&#xD;
      function and good performance status. It is also indicated for the treatment of unresectable&#xD;
      metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery&#xD;
      chemotherapy (IHAC) of Floxuridine (FUDR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigation is a pivotal, prospective, multicenter, open-label single arm study&#xD;
      evaluating treatment with hepatic arterial injection of SIR-Spheres.&#xD;
&#xD;
      Up to 100 subjects will be treated (up to 150 consented) at 10-15 clinical sites in the&#xD;
      United States. No single site will enroll more than 20% of the total study enrollment.&#xD;
&#xD;
      The population for this study includes patients diagnosed with HCC BCLC stage A, B1, B2, and&#xD;
      C with maximal single lesion size of ≤ 8cm and who are not considered suitable for treatment&#xD;
      by resection or eligible for ablation at time of study entry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A pivotal, prospective, multicenter, open-label single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>9 months</time_frame>
    <description>ORR uses a localized version of modified Response Evaluation Criteria in Solid Tumors (&quot;localized mRECIST&quot;) criteria and best response through 9 months, in patients treated with SIR-Spheres Y-90 resin microspheres.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>12 months</time_frame>
    <description>The interval from first time of response (complete response (CR) or partial response (PR)) until disease progression (PD) as defined by localized mRECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade ≥ 3 toxicity (CTCAE v5.0)</measure>
    <time_frame>2 months and 6 months</time_frame>
    <description>The severity of the adverse event should be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of liver resection</measure>
    <time_frame>Post-procedure follow-up: 1, 2, 4, 6, 9, 12, 24 months</time_frame>
    <description>Liver resection as noted on follow-up case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of liver transplant</measure>
    <time_frame>Post-procedure follow-up: 1, 2, 4, 6, 9, 12, 24 months</time_frame>
    <description>Liver transplant as noted on follow-up case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life metrics - FACT-Hep Questionnaire</measure>
    <time_frame>Pre-procedure, 2, 4, 6, 9, and 12 months</time_frame>
    <description>Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life metrics - EQ-5D-5L Questionnaire</measure>
    <time_frame>Pre-procedure, 2, 4, 6, 9, and 12 months</time_frame>
    <description>EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <condition>BCLC Stage A Hepatocellular Carcinoma</condition>
  <condition>BCLC Stage B Hepatocellular Carcinoma</condition>
  <condition>BCLC Stage C Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Open-label Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label single arm study evaluating treatment with hepatic arterial injection of SIR-Spheres.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resin microspheres containing yttrium-90 (Y-90)</intervention_name>
    <description>Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.</description>
    <arm_group_label>Open-label Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing, able, and mentally competent to provide written informed consent&#xD;
&#xD;
          2. Age 18 or older at the time of consent&#xD;
&#xD;
          3. All tumors must be measurable by CT or MRI according to localized mRECIST&#xD;
&#xD;
          4. Life expectancy ≥ 6 months (to allow for adequate completion of study procedures and&#xD;
             collection of data)&#xD;
&#xD;
          5. Diagnosis of HCC with Liver Imaging Reporting and Data System (LIRADS) 4 or 5 or by&#xD;
             histology&#xD;
&#xD;
          6. Treatment-naïve patients, including no prior locoregional therapies in the liver and&#xD;
             no systemic therapy for HCC&#xD;
&#xD;
          7. BCLC stage A, B1, B2, and C with maximal single tumor size of ≤8 cm and sum of the&#xD;
             maximal tumor dimensions of ≤12 cm with the entire tumor burden expected to be&#xD;
             treatable within the perfused volume&#xD;
&#xD;
          8. At least one lesion ≥2 cm in diameter (long axis) measured according to mRECIST&#xD;
             criteria by CT or MRI&#xD;
&#xD;
          9. Child-Pugh score of A5 or A6 at baseline&#xD;
&#xD;
         10. Albumin-bilirubin (ALBI) grade = 1 or 2 at baseline&#xD;
&#xD;
         11. Eastern Cooperative Oncology Group (ECOG) performance score of ≤1 at baseline&#xD;
&#xD;
         12. Adequate blood count, liver enzymes, and renal function at baseline&#xD;
&#xD;
               -  Platelet count &gt;50,000/microliter (patients may not receive a platelet&#xD;
                  transfusion or growth factors to increase the platelet count so that the patient&#xD;
                  may be eligible for the study)&#xD;
&#xD;
               -  White Blood Cell (WBC) ≥ 3 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin &gt; 8.5 g/dL&#xD;
&#xD;
               -  Aspartate transaminase (AST) &amp; Alanine transaminase (ALT) &lt; 5 x upper limit&#xD;
                  normal&#xD;
&#xD;
               -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
               -  Albumin &gt; 3.0 g/dL&#xD;
&#xD;
               -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
               -  International normalized ratio (INR) ≤ 2.0&#xD;
&#xD;
               -  Glomerular filtration rate (GFR) &gt; 50&#xD;
&#xD;
         13. Negative serum pregnancy test at baseline&#xD;
&#xD;
         14. Life expectancy of &gt; 3 months without any active treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients eligible for ablation or resection for their malignancy, in the opinion of&#xD;
             the investigator, at the time of screening&#xD;
&#xD;
          2. Prior systemic anti-cancer therapy (including immunotherapy and/or targeted therapy),&#xD;
             radiotherapy or use of other investigational agents for the treatment of HCC&#xD;
&#xD;
          3. Intrahepatic arteriovenous shunting (arteriovenous shunting resulting from a biopsy is&#xD;
             allowed but must be embolized during the pre-treatment mapping procedure)&#xD;
&#xD;
          4. Incompetent biliary duct system, prior biliary intervention or a compromised Ampulla&#xD;
             of Vater&#xD;
&#xD;
          5. Planned localized cancer treatment to the liver, other than the study treatment,&#xD;
             throughout the duration of the study.&#xD;
&#xD;
          6. Planned systemic cancer treatment throughout the duration of the study&#xD;
&#xD;
          7. Patients with portal vein thrombosis&#xD;
&#xD;
          8. Patients with extrahepatic disease&#xD;
&#xD;
          9. Patients with contraindications to angiography and selective visceral catheterization&#xD;
&#xD;
         10. Evidence of extrahepatic collateral supply to the tumor&#xD;
&#xD;
         11. Evidence of potential delivery of mean radiation dose &gt; 30 Gy to the lungs (single&#xD;
             treatment)&#xD;
&#xD;
         12. Evidence of any detectable 99m Tc-macroaggregated albumin (99m Tc-MAA) flow outside of&#xD;
             the liver in the abdomen, after application of established angiographic techniques to&#xD;
             stop or mitigate such flow (e.g., placing catheter distal to gastric vessels or&#xD;
             coiling)&#xD;
&#xD;
         13. Evidence that &lt; 33% of the total liver volume is disease-free and will be spared&#xD;
             SIR-Spheres treatment&#xD;
&#xD;
         14. Prior liver resection and/or liver transplant&#xD;
&#xD;
         15. Female patients who are pregnant, breastfeeding, or premenopausal and unwilling to use&#xD;
             an effective method of contraception through the 1-year follow-up; males unwilling to&#xD;
             use effective method of contraception for 30 days post-procedure&#xD;
&#xD;
         16. Medical history of clotting disorders&#xD;
&#xD;
         17. Underlying pulmonary disease requiring chronic oxygen therapy&#xD;
&#xD;
         18. Evidence of portal hypertension with ascites as seen on cross-sectional imaging or any&#xD;
             history of prior variceal bleeding within 6 months prior to screening&#xD;
&#xD;
         19. Concurrently enrolled in another study unless it is an observational,&#xD;
             noninterventional study&#xD;
&#xD;
         20. Active infection (hepatitis B (HBV) infection with ongoing HBV treatment and&#xD;
             successfully treated hepatitis C infection are allowed)&#xD;
&#xD;
         21. History of other cancer with current active treatment&#xD;
&#xD;
         22. Patients with drug or alcohol dependency (within 6 months prior to study entry) in the&#xD;
             opinion of the investigator&#xD;
&#xD;
         23. History of severe allergy or intolerance to contrast agents, narcotics, or sedatives&#xD;
&#xD;
         24. Any condition that, in the opinion of the investigator, would interfere with safe&#xD;
             delivery of the study treatment or with the interpretation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armeen Mahvash, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S. Cheenu Kappadath, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve J Chartier</last_name>
    <phone>781-721-3812</phone>
    <email>steve.chartier@sirtex.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janet Bell</last_name>
    <phone>781-721-3840</phone>
    <email>jbell@sirtex.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Miami Cardiac and Vascular Institute at Baptist Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Herrera, MD</last_name>
      <email>RaulH@baptisthealth.net</email>
    </contact>
    <contact_backup>
      <last_name>Ivette Cruz, RN</last_name>
      <email>IvetteC@baptisthealth.net</email>
    </contact_backup>
    <investigator>
      <last_name>Ripal Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riad Salem, MD</last_name>
      <phone>312-695-6371</phone>
      <email>rsalem1@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Jenkins</last_name>
      <phone>312-695-9327</phone>
      <email>kjenkins@nm.org</email>
    </contact_backup>
    <investigator>
      <last_name>Riad Salem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Lewandowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peyton Ackerman</last_name>
      <email>packerman@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carissa Walter</last_name>
      <email>cwalter2@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Zachary Collins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Johnston, RN</last_name>
      <email>jljohnston@partners.org</email>
    </contact>
    <investigator>
      <last_name>Eric Wehrenberg-Klee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Paipal-Umland, RN</last_name>
      <email>paipa002@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jill Novitzke</last_name>
      <email>novit001@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jafar Golzarian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aamir Razak</last_name>
      <email>aamir.razak@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Abashai Woodard</last_name>
      <email>abashai.woodard@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Nadolski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Soulen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Shamimi-Noori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute and Methodist Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Araceli Torres</last_name>
      <email>clinicalresearch@mhd.com</email>
    </contact>
    <contact_backup>
      <last_name>Shandra Silas</last_name>
      <email>clinicalresearch@mhd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Parvez Mantry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridgett Hobbs, RN</last_name>
      <phone>713-500-7758</phone>
    </contact>
    <contact_backup>
      <last_name>Donna Hall, RN</last_name>
      <phone>832-623-2098</phone>
    </contact_backup>
    <investigator>
      <last_name>Ahmed Kamel Abdel Aal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrick Zvavanjanja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Tapnio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihir Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexa Levey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Imaging</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brook Root</last_name>
      <phone>509-363-7627</phone>
      <email>broot@inlandimaging.com</email>
    </contact>
    <contact_backup>
      <last_name>Marilee Walker</last_name>
      <phone>509-363-7494</phone>
    </contact_backup>
    <investigator>
      <last_name>Douglas A Murrey Jr., MS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>Unresectable metastatic liver tumor</keyword>
  <keyword>SIR-Spheres microspheres</keyword>
  <keyword>Y-90 resin microspheres</keyword>
  <keyword>Barcelona Clinic Liver Cancer</keyword>
  <keyword>BCLC</keyword>
  <keyword>SIRT (Selective Internal Radiation Therapy)</keyword>
  <keyword>Liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

